CJC-1295 vs MK-677 (Ibutamoren): Cost, Access, and What Women Need to Know

What Are These Two Compounds and Why Are Women Asking About Them?

Neither CJC-1295 nor MK-677 is a prescription drug with an FDA-approved indication for women. Both circulate in the wellness and anti-aging space as growth-hormone secretagogues, meaning they coax your pituitary into releasing more of your own GH rather than injecting exogenous growth hormone directly. Interest among women has grown alongside broader GLP-1 and metabolic health conversations, particularly around body composition, sleep quality, and the muscle loss that accelerates in perimenopause.

Before going further: you cannot legally purchase either compound at a retail pharmacy in the United States. CJC-1295 is available through licensed compounding pharmacies under a provider's order, but the FDA has raised concerns about compounded peptides broadly. MK-677 is sold openly as a "research chemical," which means quality control is not guaranteed and the product you receive may not contain what the label claims. The access and cost picture is therefore more complicated than a simple price comparison.

How CJC-1295 Works

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). The version most commonly prescribed is CJC-1295 with DAC (Drug Affinity Complex), which binds to albumin in the bloodstream and extends its half-life from minutes to roughly six to eight days. Teichman et al. (2006) demonstrated that a single injection of CJC-1295 with DAC produced sustained, dose-dependent increases in GH and IGF-1 that persisted for up to eight days across a dose range of 30-120 mcg/kg in healthy adults. That study enrolled both men and women, but sex-stratified data were not reported separately, which is a real limitation when you are trying to make an informed decision as a woman.

The non-DAC version, sometimes called Modified GRF 1-29 or "Mod GRF," has a half-life of about 30 minutes and is typically injected two to three times per day, often stacked with ipamorelin to amplify the GH pulse.

How MK-677 Works

MK-677 is not a peptide at all, despite being grouped with peptide secretagogues in popular wellness culture. It is a small-molecule ghrelin receptor agonist taken orally. By mimicking ghrelin, it stimulates GH release from the pituitary and suppresses somatostatin, the hormone that normally puts the brakes on GH secretion. Murphy et al. (1998) showed that a single oral dose of MK-677 produced sustained, 24-hour elevation of GH and IGF-1 in healthy adults, with IGF-1 levels rising approximately 40% above baseline at doses of 10-50 mg daily. Again, sex-stratified data in that foundational trial were limited.

The oral route is MK-677's biggest practical advantage. No needles, no reconstitution, no cold-chain storage. That convenience comes with trade-offs covered below.

Cost and Access: A Realistic Head-to-Head

CJC-1295: What You Actually Pay and How You Get It

Obtaining CJC-1295 legally requires a licensed provider's order and a relationship with a compounding pharmacy. That pathway adds consultation fees on top of the drug itself. A realistic monthly cost breakdown looks like this:

• Provider consultation (telehealth): $75-$200 per month or per quarter
• CJC-1295 with DAC vials (compounding pharmacy): $100-$250 for a 30-day supply at common doses
• Supplies (syringes, bacteriostatic water if not pre-mixed): $10-$25
• Realistic total: $185-$475 per month in the first quarter

The FDA placed CJC-1295 on its list of "difficult to compound" substances in a 2023 draft guidance, which has made some compounding pharmacies more cautious about producing it. Access has narrowed noticeably since 2024, and some women who were stable on a compounded regimen have had to switch providers or pharmacies. This is not a stable access environment.

MK-677: Cheap, But the Grey-Market Risk Is Real

MK-677 is sold openly by dozens of online vendors as a research chemical, with prices as low as $30-$80 for a month's supply at 25 mg daily. No prescription is required in this channel, which sounds convenient until you consider that independent laboratory testing of commercially available MK-677 products has repeatedly found significant variance from labeled doses, and in some cases, contamination with other active compounds.

Compounding pharmacies do produce MK-677, typically as an oral capsule, and that route carries the same consultation overhead as CJC-1295. Compounded MK-677 from a regulated pharmacy will cost more than the grey-market version but offers meaningful quality assurance.

A practical access framework for women considering either compound:

| Factor | CJC-1295 (DAC) | MK-677 (Ibutamoren) | |---|---|---| | Requires provider order | Yes (legal use) | No (grey market) / Yes (compounding) | | Monthly drug cost | $100-$250 (compounding) | $30-$80 (grey market); $80-$150 (compounding) | | Cold storage required | Yes (refrigerated vials) | No | | Route | Subcutaneous injection | Oral | | Frequency | 1-2x per week (DAC) | Once daily | | FDA regulatory stability | Under scrutiny (difficult-to-compound list) | Not FDA-approved; grey-market supply unregulated | | Quality assurance | Compounding pharmacy USP standards | Variable (grey market), USP standards (compounding) |

Sex-Specific Physiology: Why a Woman's Biology Changes the Calculation

The Estrogen-GH Axis

Estrogen is not a passive bystander in GH physiology. It actively modulates GH secretion and IGF-1 sensitivity. During the reproductive years, estrogen amplifies pituitary GH pulse amplitude. In perimenopause and post-menopause, declining estrogen contributes meaningfully to the drop in GH pulsatility and the loss of lean mass and bone density that many women experience. Research published in endocrine journals notes this interaction, yet virtually no clinical trials of CJC-1295 or MK-677 have been designed to study women across hormonal life stages.

Oral estrogen therapy, specifically the kind taken by mouth rather than transdermally, blunts hepatic IGF-1 production. This means a woman on oral hormone therapy who also takes MK-677 or CJC-1295 may see a smaller IGF-1 rise than the trial data would predict, because oral estrogen reduces hepatic sensitivity to GH signaling. Transdermal estrogen does not carry the same effect to the same degree. This is clinically relevant if you are in perimenopause or post-menopause and on HRT.

PCOS and the Insulin-GH Connection

Women with polycystic ovary syndrome (PCOS) already have altered GH pulsatility and IGF-1 signaling compared to women without PCOS. MK-677 in particular raises insulin resistance as a documented side effect, because ghrelin receptor activation promotes glucose intolerance. For a woman with PCOS who is already managing insulin resistance, adding a compound that worsens it is a meaningful metabolic risk, not a minor footnote. CJC-1295 carries a similar but possibly lower insulin-resistance burden, since GH itself is counter-regulatory to insulin, though direct comparative data in women with PCOS do not exist.

Perimenopausal and Postmenopausal Women

The steepest natural decline in GH secretion happens in the decade around menopause. This is the life stage where interest in GH secretagogues is highest among the women who contact WomanRx. The hypothesis that raising GH and IGF-1 could offset perimenopausal body-composition changes is biologically plausible, but no published randomized controlled trial has tested CJC-1295 or MK-677 specifically in perimenopausal or postmenopausal women as a primary population. The evidence is extrapolated from studies in older adults of mixed sex or from GH replacement trials in adults with confirmed GH deficiency. Women deserve to know that distinction.

Women in Their Reproductive Years

If you are in your 20s or 30s, considering these compounds for body composition, recovery, or sleep, the conversation looks different again. GH levels in reproductively active women are generally adequate, and the rationale for supplementation is weaker. The menstrual cycle itself modulates GH: GH pulse amplitude is higher in the late follicular phase and lower in the luteal phase. There is no data on how CJC-1295 or MK-677 interacts with the normal hormonal architecture of the menstrual cycle or whether either compound disrupts cycle regularity.

Pregnancy, Lactation, and Contraception

Both CJC-1295 and MK-677 are contraindicated in pregnancy. Neither compound has human pregnancy safety data. Animal reproductive toxicity studies are incomplete or not publicly available for either compound in the peer-reviewed literature, which itself is a red flag, not reassurance.

CJC-1295 in Pregnancy

CJC-1295 has no FDA pregnancy category because it is not an approved drug. GHRH and its analogues cross biological barriers, and the developing fetus has its own GH axis that is sensitive to disruption. There is no established safe dose in pregnancy. Any woman using CJC-1295 who could become pregnant should use reliable contraception throughout treatment.

MK-677 in Pregnancy

MK-677's mechanism, mimicking ghrelin, is particularly concerning in early pregnancy. Ghrelin signaling plays a role in placentation and early embryonic development. Disrupting it with a pharmacological agonist at non-physiological doses is an unknown risk. Given that MK-677 is widely available without a prescription, unintended exposure during early pregnancy is a real scenario that women should take seriously. A positive pregnancy test is a reason to stop MK-677 immediately and contact your provider.

Lactation

Neither compound has lactation transfer data in humans. Both are plausibly transferred to breast milk given their systemic activity, but this has not been studied. The standard guidance from the Academy of Breastfeeding Medicine is that compounds without adequate lactation safety data should be avoided during breastfeeding. Treat both as incompatible with lactation until data show otherwise.

Contraception Requirement

Any woman of reproductive age using either compound should use a reliable, non-hormonal or hormonal contraceptive method throughout the course of treatment and for at least one full menstrual cycle after stopping, given the unknowns around embryonic GH axis effects.

Side-Effect Profiles Compared

CJC-1295 Side Effects

The most common side effects reported in Teichman et al. (2006) were mild and transient: injection-site redness, flushing, and headache. Approximately 16% of subjects reported transient facial flushing after injection. More significant concerns with sustained GH elevation include acromegalic symptoms if IGF-1 is pushed too high, worsening insulin resistance, fluid retention, and carpal tunnel syndrome. Women appear to be more sensitive to GH-related fluid retention, possibly because of sex-specific effects on renal sodium handling, though this is not confirmed in CJC-1295-specific data.

MK-677 Side Effects

Murphy et al. (1998) documented increased appetite (expected from a ghrelin mimetic), transient lower-extremity edema, and increases in fasting glucose and insulin. Increased appetite is dose-dependent and was notable even at 10 mg daily. For a woman who is using MK-677 partly for body-composition goals, a drug that significantly increases appetite is a practical contradiction that deserves honest acknowledgment. In longer-term studies of older adults, MK-677 at 25 mg daily raised IGF-1 levels by approximately 60% over 12 months, but also increased fasting glucose by a clinically meaningful margin in some participants.

Women with a history of insulin resistance, gestational diabetes, or PCOS are at higher risk for the glucose side effects of MK-677 specifically.

Is One Better Than the Other for Women?

There is no published randomized controlled trial directly comparing CJC-1295 and MK-677 in women. The question "is CJC-1295 better than MK-677?" does not have an evidence-based answer yet. What the available data allow is a conditional comparison:

CJC-1295 may be a better fit if you:

• Prefer a physiological GH pulse pattern (mimics normal pulsatility more closely than continuous MK-677 stimulation)
• Are comfortable with injections and cold-chain storage
• Have access to a provider willing to order and monitor it with IGF-1 lab testing
• Have insulin resistance or PCOS, where MK-677's ghrelin-driven appetite increase is particularly problematic
• Are in perimenopause and want a compound with a somewhat cleaner mechanistic fit to declining GHRH signaling

MK-677 may be a better fit if you:

• Cannot or will not self-inject
• Want the lowest possible upfront cost (grey market, with its quality caveats)
• Are pursuing improved sleep quality specifically (MK-677 has a small body of data supporting REM and slow-wave sleep improvement)
• Have no personal or family history of insulin resistance, type 2 diabetes, or PCOS

Neither is the right choice if you are pregnant, breastfeeding, have active cancer or a history of hormone-sensitive malignancy, have uncontrolled type 2 diabetes, or have untreated hypothyroidism (GH physiology is tightly coupled to thyroid status, and women have hypothyroidism at roughly five to eight times the rate of men).

Monitoring: What Labs You Need

No matter which compound a provider prescribes, responsible use requires baseline and follow-up laboratory monitoring. At minimum:

• IGF-1 (insulin-like growth factor 1): Baseline, then at 6-8 weeks. Target is mid-to-upper range for your age, not supraphysiologic.
• Fasting glucose and insulin: Baseline and at 3 months, particularly with MK-677.
• HbA1c: Baseline for women with PCOS, obesity, or any metabolic risk factor.
• TSH and free T4: Thyroid function affects GH axis interpretation. Women should have thyroid status confirmed before starting either compound.
• Estradiol and FSH (where relevant): For perimenopausal women, knowing where you are hormonally contextualizes any IGF-1 response you see.

IGF-1 should not exceed the upper limit of normal for your age and sex. Supraphysiologic IGF-1 is associated with increased risk of colorectal and premenopausal breast cancer in epidemiological data, as noted in analyses indexed on PubMed. This is not a reason to panic, but it is a reason to monitor.

Can You Switch Between Them?

Switching from CJC-1295 to MK-677, or vice versa, is technically feasible, but there is no published washout protocol or switching guideline. CJC-1295 with DAC has a half-life of approximately six to eight days, meaning residual GH stimulation from the last injection persists for up to two weeks. Starting MK-677 immediately after stopping CJC-1295 would layer two GH-stimulating mechanisms during that window, which is not studied and not recommended without provider oversight.

A conservative approach, supported by the pharmacokinetics reported in Teichman et al. (2006), would be to wait two full half-lives (approximately 14-16 days) after the last CJC-1295 injection before starting MK-677, and to recheck IGF-1 at the start of MK-677 to establish a true baseline.

The Evidence Gap Women Deserve to Hear

Women have been historically under-represented in peptide and growth-hormone research. The two foundational trials most cited for these compounds, Teichman et al. (2006) and Murphy et al. (1998), enrolled mixed-sex populations but did not publish sex-stratified efficacy or safety data. No published trial has studied CJC-1295 or MK-677 specifically in women with PCOS, in perimenopausal women, in women on hormone therapy, or in postpartum women. Every claim about these compounds working "for women" is extrapolated from data that was not designed to answer that question.

WomanRx editorial board member Dr. Elena Vasquez, a reproductive endocrinologist, puts it plainly: "We have biologically plausible reasons to think GH secretagogues could benefit women in perimenopause, but we do not have the trials to tell us the right compound, the right dose, or the right monitoring interval for a woman at any specific hormonal life stage. Prescribing these compounds in women right now is an act of informed extrapolation, and patients should understand that clearly before they start."

That honesty matters. If a provider tells you the evidence for these compounds in women is clear and well-established, that is a signal to ask more questions.